Epithelial mesenchymal transition in colorectal cancer: Seminal role in promoting disease progression and resistance to neoadjuvant therapy

被引:50
作者
Bhangu, Aneel [2 ,3 ]
Wood, Gemma [1 ]
Mirnezami, Alex [4 ]
Darzi, Ara [5 ]
Tekkis, Paris [2 ,3 ]
Goldin, Robert [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Ctr Pathol, London, England
[2] Royal Marsden Hosp, Dept Colorectal Surg, London SW3 6JJ, England
[3] Univ London Imperial Coll Sci Technol & Med, Div Surg, London, England
[4] Univ Southampton, Canc Res UK Ctr, Canc Sci Div, Southampton, Hants, England
[5] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Biosurg & Surg Technol, Acad Surg Unit, London, England
来源
SURGICAL ONCOLOGY-OXFORD | 2012年 / 21卷 / 04期
关键词
Epithelial mesenchymal transition; Colorectal cancer; Rectal cancer; E-CADHERIN; BETA-CATENIN; PROGNOSTIC MARKER; TRANSCRIPTIONAL REGULATION; MESORECTAL EXCISION; CHROMOSOME; 18Q; ALLELIC LOSS; IN-VITRO; SMAD4; INVASION;
D O I
10.1016/j.suronc.2012.08.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Epithelial mesenchymal transition (EMT) may be physiological as part of embryological development, or pathological as part of cancer development. It is one of the key initiating events in the metastatic cascade. EMT has profound effects on tumour cell invasiveness, proliferation and motility. In the present article we aimed to review the potential role of EMT as a process to explain colorectal cancer progression and resistance to neoadjuvant therapy. Methods: Extensive literature searches were performed in Pubmed, EMBASE and Google Scholar databases to identify relevant articles published before March 2012. Results: There is adequate evidence to support the complex upstream signalling alterations needed for EMT to occur in colorectal cancers. Changes of EMT are likely to be found at the tumour invasive front: the deepest, growing tumour margin. Loss of E-cadherin at the cell membrane causes loss of cellular integrity, with subsequent migration of malignant cells and tumour budding. These processes are associated with metastases and recurrence of colorectal cancer. There is early evidence from a limited number of studies that resistance to neoadjuvant therapy in colorectal cancer is associated with changes of EMT. However, there is a lack of supporting evidence originating from human colorectal cancer tissues. Conclusions: Emerging evidence demonstrates that development of EMT in colorectal cancer leads to an aggressive phenotype that may promote metastatic spread, and augment treatment resistance during neoadjuvant therapy. A clearer understanding of the processes and role of EMT in colorectal cancer may also highlight novel therapeutic strategies. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:316 / 323
页数:8
相关论文
共 70 条
[1]   In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines [J].
Adhim, Z. ;
Matsuoka, T. ;
Bito, T. ;
Shigemura, K. ;
Lee, K-M ;
Kawabata, M. ;
Fujisawa, M. ;
Nibu, K. ;
Shirakawa, T. .
BRITISH JOURNAL OF CANCER, 2011, 105 (03) :393-402
[2]  
Ahn BK, 2011, HEPATOGASTROENTEROLO, V58, P112
[3]   SMAD4 as a prognostic marker in colorectal cancer [J].
Alazzouzi, H ;
Alhopuro, P ;
Salovaara, R ;
Sammalkorpi, H ;
Järvinen, H ;
Mecklin, JP ;
Hemminki, A ;
Schwartz, S ;
Aaltonen, LA ;
Arango, D .
CLINICAL CANCER RESEARCH, 2005, 11 (07) :2606-2611
[4]   MicroRNA: future perspectives in colorectal cancer [J].
Altomare, Donato F. ;
Di Lena, Maria ;
Giuratrabocchetta, Simona .
COLORECTAL DISEASE, 2012, 14 (02) :133-134
[5]   Prognostic Value of Reduced SMAD4 Expression in Patients With Metastatic Colorectal Cancer Under Oxaliplatin-Containing Chemotherapy: A Translational Study of the AIO Colorectal Study Group [J].
Baraniskin, Alexander ;
Munding, Johanna ;
Schulmann, Karsten ;
Meier, Dominik ;
Porschen, Rainer ;
Arkenau, Hendrik-Tobias ;
Graeven, Ullrich ;
Schmiegel, Wolff ;
Tannapfel, Andrea ;
Reinacher-Schick, Anke .
CLINICAL COLORECTAL CANCER, 2011, 10 (01) :24-29
[6]   A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas [J].
Baron, John A. ;
Sandler, Robert S. ;
Bresalier, Robert S. ;
Quan, Hui ;
Riddell, Robert ;
Lanas, Angel ;
Bolognese, James A. ;
Oxenius, Bettina ;
Horgan, Kevin ;
Loftus, Susan ;
Morton, Dion G. .
GASTROENTEROLOGY, 2006, 131 (06) :1674-1682
[7]   Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus A Systematic Review and Meta-analysis [J].
Barone, Bethany B. ;
Yeh, Hsin-Chieh ;
Snyder, Claire F. ;
Peairs, Kimberly S. ;
Stein, Kelly B. ;
Derr, Rachel L. ;
Wolff, Antonio C. ;
Brancati, Frederick L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (23) :2754-2764
[8]   Does use of metformin protect against cancer in Type 2 diabetes mellitus? [J].
Bo, S. ;
Benso, A. ;
Durazzo, M. ;
Ghigo, E. .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2012, 35 (02) :231-235
[9]   Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study [J].
Brown, G. ;
Daniels, I. R. ;
Heald, R. J. ;
Quirke, P. ;
Blomqvist, L. ;
Sebag-Montefiore, D. ;
Moran, B. J. ;
Holm, T. ;
Strassbourg, J. ;
Peppercorn, P. D. ;
Fisher, S. E. ;
Mason, B. .
BRITISH MEDICAL JOURNAL, 2006, 333 (7572) :779-782
[10]   MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression [J].
Bullock, Marc D. ;
Sayan, Abdulkadir E. ;
Packham, Graham K. ;
Mirnezami, Alex H. .
BIOLOGY OF THE CELL, 2012, 104 (01) :3-12